Astrazeneca has scored a hit with Imfinzi in the Caspian trial, but the results are unlikely to endanger Roche's Tecentriq.
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
A win with a tenapanor combo could bode well for the project’s monotherapy chances.
Tocagen’s Toca-5 trial has survived two interim reviews, and faces final readout by the end of this year.
Carmat says its artificial heart is the best such device in existence. But time is short, and so is money.
With decent efficacy and clean safety in the Orion-11 trial, questions now turn to pricing and whether The Medicines Company will be taken out.
With a narrow primary endpoint miss and a 15% decrease in hospitalisations, Novartis is adamant that Entresto can get approved in HFpEF.
Lilly is awaiting the first set of pivotal data with the cytokine agent it bought from Armo last year, while Biohaven heads for migraine catalysts.
The extensively overhauled Tulip-2 study of anifrolumab in lupus is an unexpected success.